Skip to content
About us
Overview
Our Team
Management
Projects
Small-molecule inhibitors and modulators of immune checkpoint receptors
Multifunctional fusion proteins for cancer immunotherapy
Combination cancer immunotherapy
EU – funded projects
Technology
Rational drug design
Protein engineering and recombinant protein production
Compounds synthesis
Hit-to-lead drug development
HTRF
ELISA
NMR
Products & Services
Recombinant proteins
Library of recombinant immune checkpoint receptors
Service
Service platform for the immune checkpoint inhibitors/modulators development
Protein engineering and recombinant protein production
Contact
Careers
Search for:
Hit-to-lead drug development
Home
/
Hit-to-lead drug development
Hit-to-lead drug development
administraT0R
2020-06-25T11:27:59+00:00
Discovery methods
HTRF
ELISA
NMR
Recepton’s integrated panel of drug discovery methods includes:
NMR fragment-based drug discovery
High throughput screening by HTRF
ELISA
AIDA-NMR
Cell-based assays
ADME